GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nascent Biotech Inc (OTCPK:NBIO) » Definitions » Forward PE Ratio

Nascent Biotech (Nascent Biotech) Forward PE Ratio : 0.00 (As of May. 28, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Nascent Biotech Forward PE Ratio?

Nascent Biotech's Forward PE Ratio for today is 0.00.

Nascent Biotech's PE Ratio without NRI for today is 0.00.

Nascent Biotech's PE Ratio for today is 0.00.


Nascent Biotech Forward PE Ratio Historical Data

The historical data trend for Nascent Biotech's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nascent Biotech Forward PE Ratio Chart

Nascent Biotech Annual Data
Trend
Forward PE Ratio

Nascent Biotech Quarterly Data
Forward PE Ratio

Competitive Comparison of Nascent Biotech's Forward PE Ratio

For the Biotechnology subindustry, Nascent Biotech's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nascent Biotech's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nascent Biotech's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Nascent Biotech's Forward PE Ratio falls into.



Nascent Biotech Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Nascent Biotech  (OTCPK:NBIO) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Nascent Biotech Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Nascent Biotech's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Nascent Biotech (Nascent Biotech) Business Description

Traded in Other Exchanges
N/A
Address
631 US Hwy 1, Suite 407, N Palm Beach, FL, USA, 33408
Nascent Biotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is focused on the development and delivery of human antibodies and cytokine responses to the treatment of cancer. The company's products include Pritumumab, CLNH5, and MultiPharm. The company is actively engaged in the development of Pritumumab which would be used for the treatment of brain cancer and pancreatic cancer. The company is also exploring the use of Pritumumab against other viruses.
Executives
Lowell Thomas Holden director, officer: CFO 631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Sean Carrick director, officer: President 631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Brandon Price director, officer: Senior VP Business Development 6330 NANCY RIDGE DR., SUITE 105, SAN DIEGO CA 92121
Douglas John Karas director 631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Mark Glassy director, officer: CEO 6330 NANCY RIDGE DR., SUITE 105, SAN DIEGO CA 92121